Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter

Authors:

Abstract
No abstract available
Funding Information
  • Univerzita Karlova v Praze (SVV/2021/260 549)
  • Grantová Agentura České Republiky (20-20414Y)
  • European Regional Development Fund (85009748)

This publication has 55 references indexed in Scilit: